Tetraphase reports Phase I safety data for antibiotic TP-271

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) reported data from 56 healthy volunteers in a double-blind, placebo-controlled Phase I trial showing that single doses of 0.15 to 5 mg/kg doses of IV TP-271 were well tolerated with no serious adverse events reported. The most common adverse events reported were nausea and vomiting. Data were presented at the American Society for Microbiology meeting in New Orleans. The trial is evaluating safety and pharmacokinetics of TP-271. The company is developing the product to treat serious bacterial infections, including respiratory infections caused by multidrug-resistant pathogens...